Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+1.39%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-10-30 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
25
Jun
Astellas Pharma Inc. JP3942400007
2026-06-24 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received approval in Europe for combination therapy with pembrolizumab for resectable muscle-invasive bladder cancer that is unsuitable for cisplatin, providing a new treatment option as adjuvant therapy before and after surgery.”
25
Jun
Kyowa Kirin Co.,Ltd. JP3256000005
2026-06-24 Kyowa Kirin Co.,Ltd. “Key data from the Phase 3 clinical trial "PROPEL 3" of the oral drug infigratinib for achondroplasia were presented at ICCBH 2026 (736KB).”
25
Jun
Kyowa Kirin Co.,Ltd. JP3256000005
2026-06-24 Kyowa Kirin Co.,Ltd. “The FGFR1-3 inhibitor KK8398 (infigratinib) has received orphan drug designation in Japan for the treatment of achondroplasia without epiphyseal plate closure (546KB).”
20
Jun
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-06-19 DAIICHI SANKYO COMPANY,LIMITED “Personnel changes effective July 1, 2026 (155KB) PDF file will open in a new window.”
20
Jun
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-06-19 DAIICHI SANKYO COMPANY,LIMITED “The PDF file regarding the organizational changes effective July 1, 2026 (174.1KB) will open in a new window.”
20
Jun
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-06-19 CHUGAI PHARMACEUTICAL CO.,LTD. “Sparsentan has submitted an application for manufacturing and marketing approval in Japan for the treatment of IgA nephropathy.”
20
Jun
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-06-19 CHUGAI PHARMACEUTICAL CO.,LTD. “Regarding the approval of the anti-CD20 monoclonal antibody "Rituxan®" for adult-onset, frequently relapsing, or steroid-dependent nephrotic syndrome.”
20
Jun
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-06-19 CHUGAI PHARMACEUTICAL CO.,LTD. “Avastin has received approval for an additional indication, becoming the world's first treatment for neurofibromatosis type 2.”
20
Jun
Shionogi & Co.,Ltd. JP3347200002
2026-06-19 Shionogi & Co.,Ltd. “Regarding the approval of additional pediatric dosages for the anti-coronavirus (SARS-CoV-2) drug Zocova® in Japan.”
20
Jun
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-06-19 Sumitomo Pharma Co.,Ltd. “Novo Nordisk Pharma and I have a promotional partnership underway for Ugobi Subcutaneous Injection, which has received approval for metabolic disorder-associated steatohepatitis (MASH).”
19
Jun
Shionogi & Co.,Ltd. JP3347200002
2026-06-18 Shionogi & Co.,Ltd. “Preliminary report on the positive results of the global Phase 3 clinical trial (OASIS trial) of the novel antifungal drug orolofim.”
17
Jun
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-06-16 Sumitomo Pharma Co.,Ltd. “Announcement regarding the latest data presentation on the investigational anticancer drugs nuvisertib and enzomenib at the European Hematology Association (EHA) 2026 conference.”
16
Jun
Otsuka Holdings Co.,Ltd. JP3188220002
2026-06-15 Otsuka Holdings Co.,Ltd. “Regarding the completion of the acquisition of Transcend Therapeutics.”
16
Jun
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-06-15 DAIICHI SANKYO COMPANY,LIMITED “The announcement regarding the approval of Vanflita® (quizartinib) for sale in China (161.7KB) will open in a new window as a PDF file.”
16
Jun
Eisai Co.,Ltd. JP3160400002
2026-06-15 Eisai Co.,Ltd. “With support from the UK government's Life Sciences Innovative Manufacturing Fund, we are making a strategic investment in our Hatfield UK facility—a strategic investment aimed at bringing in-house production and packaging systems for pharmaceuticals requiring temperature control.”
13
Jun
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-06-12 CHUGAI PHARMACEUTICAL CO.,LTD. “Tecentriq has applied for an expanded indication as maintenance therapy after curative chemoradiotherapy in locally advanced esophageal cancer.”
13
Jun
Shionogi & Co.,Ltd. JP3347200002
2026-06-12 Shionogi & Co.,Ltd. “Announcement regarding investment in Dioseve Co., Ltd. through CVC.”
13
Jun
Kyowa Kirin Co.,Ltd. JP3256000005
2026-06-12 Kyowa Kirin Co.,Ltd. “Favorable clinical trial data on the long-term follow-up of ziftomenib/7+3 combination therapy in newly diagnosed AML will be presented orally at the 2026 EHA Annual Meeting (859KB).”
12
Jun
Otsuka Holdings Co.,Ltd. JP3188220002
2026-06-11 Otsuka Holdings Co.,Ltd. “58 years after its launch, Bon Curry's familiar taste is being passed on to the next generation. Otsuka Foods' Lake Biwa Research Institute has developed a taste and recipe prediction AI system called "Oishisa LENS" and has begun using it for technology transfer and product design.”
11
Jun
Otsuka Holdings Co.,Ltd. JP3188220002
2026-06-10 Otsuka Holdings Co.,Ltd. “Otsuka Chemical and Gutenberg are collaborating with three student groups participating in the NHK Student Robot Contest using 3D printing technology.”